Metastasis is a complex multistep process, which requires the concerted action of many genes and is the primary cause of cancer death. Both pathways that regulate metastasis enhancement and those that regulate its suppression contribute to the tumour dissemination process. To identify new metastasis suppressors, we set up a forward genetic screen in a mouse model. We transduced a genome-wide RNA interference (RNAi) library into the non-metastatic 168FARN breast cancer cell line and orthotopically transplanted the cells into mouse mammary fat pads. We then selected cells that could metastasize to the lung and identified an RNAi for the KLF17 gene. Conversely, we demonstrate that ectopic expression of KLF17 in a highly metastatic 4T1 breast cancer cell line inhibits the ability of cells to metastasize from the mammary fat pad to the lung. We also show that suppression of KLF17 expression promotes breast cancer cell invasion and epithelial-mesenchymal transition (EMT), and that KLF17 protein functions by directly binding to the promoter region of Id1 (which encodes a key metastasis regulator in breast cancer) to inhibit its transcription. Finally, we demonstrate that KLF17 expression is significantly downregulated in primary human breast cancer samples and that the combined expression pattern of KLF17 and Id1 can serve as a potential biomarker for lymph node metastasis in breast cancer.
Metastasis, the spread of cells from a primary tumour site followed by growth of secondary tumours in a new location, is responsible for most cancer deaths and remains one of the most poorly understood processes in cancer biology [1] [2] [3] [4] [5] [6] [7] [8] . Metastasis occurs through a multistep process, including invasion of local tissues, entrance of cancer cells into the blood stream, survival in the circulation, exit from blood vessels, initiation and maintenance of micrometastases at distant sites and, finally, metastatic tumour development [1] [2] [3] 8, 9 . This process depends on balancing metastasis promotion and suppression programs in the tumour cells [1] [2] [3] [4] . These cells must both overcome the cellular suppression machinery and activate their promotion pathways to become metastatic 4, 10, 11 . Identification and characterization of the genes that suppress metastasis and of the mechanisms by which this suppression occurs will lead to the identification of new markers of metastasis and potential therapeutic targets for prevention and treatment.
Forward genetic screens provide an unbiased approach to the identification of genes associated with a phenotype of interest [12] [13] [14] [15] . RNAi technology and the availability of genome sequences of model organisms have facilitated the construction of RNAi libraries and provided powerful tools for loss-of-function (RNAi-mediated knockdown) screens at the genome-wide level [16] [17] [18] . Because of the complexity of the metastatic process, application of forward genetic screens to animal models of metastasis should assist in the identification of genes that are critical to this process. Here we report the identification of KLF17 as a metastasis suppressor in human breast cancer.
REsuLTs
Identification of KLF17 as a metastasis suppressor using a forward genetic screen in an orthotopic mouse model 168FARN cells, originally isolated from a single mouse mammary tumour that arose spontaneously in a wild-type Balb/cJ mouse [19] [20] [21] [22] , were chosen for the initial screen as they are known to be deficient in the early steps of metastasis (that is, tumour migration and invasion), but have full metastatic potential once they reach the blood stream and enter the lung 23 . Thus, they are suitable for the isolation of genes that promote or suppress the early steps of metastasis, where more effective approaches to controlling metastasis might be developed. We used a genome-wide lentiviral RNAi library consisting of short hairpin RNAs (shRNAs) targeting 40,000 mouse genes for our screen, as it is possible to easily retrieve them from the positively selected cells using PCR 23 . We transplanted the transduced 168FARN tumour cells into mouse mammary fat pads, where they would normally remain. RNAi knockdown of a metastasis suppressor gene should allow the cells to metastasize to the lung. Lung metastases served as the selection system for these studies (Fig. 1a) . A proof-of-concept experiment was carried out using five Balbc/J mice, one of which developed a lung metastasis in 7 weeks (Fig. 1b) . The one shRNA retrieved from the metastatic cells was found to correspond to KLF17 (Krüppel-like transcription factor 17). We carried out the following validation studies to support the identification of KLF17 as a negative regulator of metastasis.
KLF17 is a negative regulator of metastasis KLF17 (also known as ZNF393) is a member of the Sp/KLF (specificity protein/Krüppel-like factor) zinc-finger protein family, which comprises transcription factors with diverse functions [24] [25] [26] . KLF family members can function as either activators or repressors, depending on the promoters they bind to and the cellular proteins they interact with 24, 25 . They are critical regulators of various cellular processes, including reprogramming of differentiated cells to stem cells 27 , erythropoiesis 28, 29 and cell survival 30 . Moreover, some KLF family members have been implicated in tumour development [31] [32] [33] . The murine homologue of KLF17 is believed to have a role in gametogenesis and early embryogenesis based on its expression in early embryos, testes and ovaries 34 , however, there is little functional information on either human or mouse KLF17.
To validate that KLF17 expression promotes metastasis, we generated a luciferase-tagged 168FARN cell line that stably expressed KLF17 shRNA. The suppression of KLF17 expression was confirmed by immunoblotting ( Supplementary Information, Fig. 1A ). The KLF17-knockdown cells were then transplanted into mouse mammary fat pads using the same procedure as in the initial screen. The growth of primary tumours was similar in both KLF17-knockdown and control cells before week 6, but was higher in the knockdown cells after 6 weeks (Fig. 1c) . The KLF17-knockdown cells in the primary tumours could be seen to invade neighbouring healthy muscle and fat tissues ( Supplementary Information, Fig. 1B) , demonstrating their Supplementary Information, Fig. 1C ). Histological analysis confirmed the formation of micrometastases in the lungs (Fig. 1e) . KLF17 knockdown had little effect on the growth of metastases after transplantation through the tail vein ( Supplementary Information, Fig. 1D ), further supporting the hypothesis that KLF17 acts in the early steps of metastasis. To further confirm that the enhanced metastatic potential was specifically due to inhibition of KLF17 expression, we introduced KLF17 cDNA lacking the 3´UTR region, which includes the target sequence for KLF17 shRNA, into 168FARN cells stably expressing KLF17 shRNA. The expression of KLF17 protein was confirmed by immunoblotting ( Supplementary Information,  Fig. 1E ). These cells were then transplanted into mouse mammary fat pads. The metastatic phenotype showed by the KLF17-knockdown cells was completely abolished by introduction of the KLF17 cDNA lacking the target sequence, demonstrating that the induction of metastases in 168FARN cells was indeed due to the suppression of KLF17 expression (Fig. 1d ).
To determine whether KLF17 had a similar role in the metastasis of human breast cancers, we generated a luciferase-tagged human breast cancer MCF7 cell line stably expressing KLF17 shRNA, and confirmed loss of protein expression by immunoblotting ( Supplementary Information,  Fig. 1F ). The KLF17-knockdown MCF7 cells were transplanted into the mammary fat pads of severe combined immunodeficient (SCID) mice. There was no significant difference in primary tumour growth in KLF17-knockdown cells compared with control cells, which expressed non-targeting shRNA (Fig. 1f) . Lung micrometastases developed 8-10 weeks after transplantation in the KLF17-knockdown cells, whereas MCF7 control cells did not metastasize ( Fig. 1g, h; Supplementary Information,  Fig. 1G ), demonstrating that knockdown of KLF17 expression also promotes metastasis in human breast cancer cells.
To further validate the metastasis-suppressing activity of KLF17, we did the converse experiment and generated a mouse 4T1 cell line that stably overexpressed mouse KLF17 cDNA. Both 4T1 and 168FARN cells were originally isolated from the same mouse mammary tumour, but have dramatically different metastasis potentials [19] [20] [21] [22] . Overexpression of KLF17 in 4T1 cells was confirmed by immunoblotting ( Supplementary Information,  Fig. 1H ). Although both cell lines are capable of forming primary mammary carcinomas, only 4T1 cells form metastases after mammary pad injection. After transplantation into mammary fat pads, 4T1 cells normally form visible metastatic nodules in the lung with high efficiency 5, [19] [20] [21] [22] [23] . The 4T1 cells stably overexpressing KLF17 protein were transplanted into mouse mammary fat pads and after 4-5 weeks the lung surface was examined for the presence of metastatic nodules. Although KLF17 overexpression was shown not to affect 4T1 primary tumour growth in vivo (Fig. 2a) , the numbers of metastatic nodules were significantly less from 4T1 cells overexpressing KLF17 than from those expressing the control vector, demonstrating that KLF17 functions to suppress metastasis in vivo (Fig. 2b ,c) .
Downregulation of KLF17 promotes epithelial-mesenchymal transition (EMT)
Because 168FARN cells are defective in the early steps of tumour metastasis [19] [20] [21] [22] [23] , we further examined whether KLF17 might have a role in the initial invasion of the tumour cells into neighbouring tissues through processes such as migration, invasion and EMT. The effects of KLF17 knockdown on these processes were evaluated in a transwell migration assay. Knockdown of KLF17 expression resulted in a clear and potent migratory phenotype in both mouse breast cancer and human breast cancer cells when compared with their respective control cells (Fig. 3a) . Similar results were obtained in a Matrigel invasion assay (Fig. 3b) , indicating that knockdown of KLF17 promotes tumour cell migration and invasion.
EMT, a process by which tumour-associated epithelial cells obtain mesenchymal features (resulting in reduced cell-cell contact and increased motility), has a critical role in metastasis 35, 36 . Several factors that promote this process have been identified 5, [37] [38] [39] [40] , however, the roles of factors negatively regulating EMT remain unclear. To assess the contribution of KLF17 to EMT regulation, a mouse mammary epithelial cell line (NMuMG) stably expressing KLF17 shRNA was generated, and knockdown was confirmed by immunoblotting ( Supplementary Information, Fig. 2A ). After KLF17 knockdown, NMuMG cells showed spindle-like, fibroblastic morphology, one of the main characteristics of EMT ( Fig. 3c; Supplementary Information, Fig. 2B ). Expression of both epithelial and mesenchymal molecular markers was confirmed by immunoblotting and immunocytochemistry. Expression of epithelial markers, E-cadherin, zonula occludens-1 (ZO-1) and β-catenin, was significantly reduced in KLF17-knockdown cells (Fig. 3d) , and E-cadherin and ZO-1 was lost from cell-cell contacts (Fig. 3e) . In contrast, expression of mesenchymal markers, fibronectin, vimentin and N-cadherin (which positively correlate with EMT), was dramatically upregulated in KLF17-knockdown cells (Fig. 3d, e) . We further confirmed the EMT phenotype after KLF17 knockdown in an immortalized human mammary epithelial cell 
Id1 is directly regulated by KLF17 and is required for KLF17 function
To identify the downstream molecules regulated by KLF17, gene expression studies were performed. Gene expression was analysed in 168FARN cells that either stably expressed KLF17 shRNA, overexpressed KLF17 cDNA or carried a control vector. We were specifically interested in genes whose expression was increased in KLF17-knockdown cells but decreased in KLF17-overexpressing cells, or vice versa (Supplementary Information, Table S1 ). Among the significant genes that met these criteria, the expression of Id1 (inhibitor of DNA binding 1) was found to be upregulated in KLF17-knockdown cells and downregulated in KLF17-overexpressing cells. Id1 is a member of the Id protein family, which comprises dominant negative regulators of the basic helix-loop-helix family of transcription factors [41] [42] [43] . Id1 is a key regulator of development, the cell cycle and tumorigenesis [41] [42] [43] . Recent findings suggest that Id1 is deregulated in various types of cancers and is important in the development of embryonic stem cell-like phenotypes in cancer cells 44 . Id1 has also been shown to have a critical role Number of cells migrated P = 0.0005
Number of cells migrated Number of cells invaded Number of cells invaded in EMT, angiogenesis, invasion and metastasis [45] [46] [47] and to cooperate with oncogenic Ras to induce mammary tumour metastasis 48 . Id1 upregulation has been associated with poor clinical outcome in breast cancer 49, 50 and suppression of Id1 by shRNAs or chemical inhibitors blocks invasion and metastasis in breast cancer [51] [52] [53] . Because both animal models and clinical studies indicate that Id1 is a key regulator of breast cancer development and metastasis, we further investigated interactions between KLF17 and Id1.
It has been shown that KLF17 binds to the DNA consensus sequence (5´-CACCC-3´) to regulate transcription 26 . We scanned the promoter region of mouse Id1 for the KLF17 consensus sequence and found two potential binding sites: -2127 to -2110 (site 1) and -1327 to -1316 (site 2) from the transcriptional initiation site (Fig. 4a) . We cloned the promoter region of mouse Id1 upstream of a luciferase gene in a reporter plasmid (Fig. 4a ) and co-transfected the KLF17 cDNA construct and the Id1 reporter construct into 168FARN cells. KLF17 expression suppressed the luciferase signal from the reporter plasmid, which was driven by the Id1 promoter region, by 63% (Fig. 4b ) in a dose-dependent manner ( Supplementary Information, Fig. 3A) . Mutation of the potential KLF17 binding site 1 relieved the suppression by KLF17 (Fig. 4b) , whereas mutation of binding site 2 did not (Fig. 4b) . Thus KLF17 can suppress Id1 transcription and requires binding site 1, but not 2.
To further investigate whether KLF17 directly binds to site 1 of the Id-1 promoter region, we carried out an electrophoretic mobility shift assay (EMSA) using recombinant GST-KLF17 protein expressed in Escherichia coli, and an isotope-labelled DNA probe comprising site 1. GST-KLF17 bound specifically to the wild-type binding site 1 (Fig. 4c, lane 4) , but not to the mutated site 1 (Fig. 4c, lane 5) . Moreover, competition with an unlabelled, wild-type site 1 oligonucleotide blocked the binding of GST-KLF17 to site 1 (Fig. 4c, lane 6) , whereas the addition of an unlabelled, mutated site 1 oligonucleotide had no effect on the binding of GST-KLF17 to site 1 (Fig. 4c, lane 7) . These results demonstrate that KLF17 suppresses Id1 expression by directly binding to the Id1 promoter region.
To determine whether KLF17 binds to the Id1 promoter region in vivo, we performed chromatin immunoprecipitation (ChIP) analysis using an anti-KLF17 antibody. The Id1 promoter region where KLF17 binds in EMSA was significantly enriched when compared with a control IgG ChIP as assessed by quantitative real-time PCR, further demonstrating that Id1 is a direct target of KLF17 in vivo ( Fig. 4d ; Supplementary Information, Fig. 3B) .
To examine the effect of Id1 upregulation on tumour metastasis in vivo, we generated luciferase-tagged mouse 168FARN and human MCF7 cell lines stably expressing mouse or human Id1 cDNAs, respectively. Id1 expression in the 168FARN and MCF7 cells was confirmed by immunoblotting ( Supplementary Information, Fig. 3C, D) and the overexpressing cells were transplanted into the mammary fat pads of Balb/c or SCID mice, respectively. After transplantation, lung metastases developed from Id1-upregulated cells but not from control cells, demonstrating that upregulation of Id1 expression promotes tumour metastasis in vivo (Fig. 4e, f) . Finally, we examined the importance of Id1 upregulation in the process of KLF17-knockdown-induced migration and invasion. We used shRNA to knockdown Id1 expression in 168FARN KLF17-knockdown cells. Downregulation of Id1 in 168FARN KLF17-knockdown cells reversed the expression of epithelial and mesenchymal markers ( Supplementary  Information, Fig. 2c ), indicating Id1 is a major mediator of KLF17-induced EMT. Figure 4g and h shows that knockdown of Id1 expression in 168FARN cells, in which KLF17 expression is suppressed, significantly reduces the number of migrating and invading cells. No metastasis occurred when KLF17 and Id1 double-knockdown 168FARN cells were transplanted into mouse mammary fat pads ( Fig. 4i; Supplementary Information, Fig. 3E ). Together, these results suggest that knockdown of KLF17 promotes tumour metastasis, at least in part, by increasing Id1 expression and that KLF17 is a negative regulator of Id1 expression.
As it has also been shown that Id1 cooperates with oncogenic Ras (HRasG12V) to promote metastasis 48 , we examined whether KLF17-knockdown also influences the function of HRasG12V in tumour metastasis. We found no primary tumour growth when NMuMG cells or NMuMG cells stably expressing KLF17 shRNA were transplanted into mouse mammary fat pads (data not shown). In contrast, NMuMG cells stably expressing both KLF17 shRNA and oncogenic HRasG12V, or HRasG12V alone produced both primary tumours and lung metastases ( Supplementary Information, Fig. 4A ). However, the number of lung metastases in the KLF17 shRNA + HRasG12V group was 50% higher than in the HRasG12V-alone group ( Supplementary Information, Fig. 4B ). In addition, 50% of mice transplanted with NMuMG cells stably expressing KLF17 shRNA + HRasG12V also developed metastases in the liver, kidney and colon, whereas NMuMG cells expressing HRasG12V alone did not produce metastases in any organ except the lung ( Supplementary  Information, Fig. 4A ). These results indicate that knockdown of KLF17 enhances tumour metastasis promoted by oncogenic HRasG12V. We further examined the role of Ras in cell migration and invasion in tumour cells when KLF17 expression is downregulated. We cloned and sequenced the coding region of HRas, NRas and KRas in 168FARN cells. These cells harbour a I55Y mutation in HRas and no mutations in either NRas or KRas. To our knowledge, this HRas mutation has not been reported and it is not known whether this mutation has any effect on HRas activity. We then used the Ras farnesylation inhibitor FTI-277 to assess Ras functions in cell migration and invasion. Incubation of 168FARN cells stably expressing KLF17 shRNA with FTI-277 did not affect the expression of either epithelial or mesenchymal markers (data not shown). However, the migratory and invasive activities of these cells were significantly reduced in our in vitro migration and invasion assays ( Supplementary Information, Fig. 4c ), indicating that Ras has an important role in tumour cell migration and invasion that is enhanced when KLF17 expression is downregulated.
KLF17 is downregulated in human breast cancer tumour samples
Finally, we examined expression levels of KLF17 and Id1 in breast cancer cell lines and primary human breast cancer tumour samples. The invasive capability of seven breast cancer cell lines was determined in a Matrigel assay (data not shown). KLF17 expression was lower in breast cancer cell lines with an invasive phenotype and Id1 expression was higher in these cell lines (Fig. 5a ). Pearson correlation analysis indicated that expression of KLF17 and Id1 was inversely correlated in the cell lines (r = -0.75, P = 0.05). Next, we examined expression of these two genes in 93 human primary breast tumours with known lymph node metastasis status. Of the tumours, 46 samples were lymph node positive and 47 samples were lymph node negative at the time of diagnosis. We found that the mean expression of KLF17 in the patients with histologically confirmed lymph node metastases was significantly lower than the mean expression in patients without metastases (Table 1 , P < 0.001; Supplementary Information, Fig. 5 and Tables S2-4) . Conversely, the mean expression of Id1 was higher in the patients with lymph node metastases than in those with no metastases (Table 1 , P < 0.001; Supplementary Information, Fig. 5 , and Tables S2-4 ). More importantly, based on the multivariate analysis, KLF17 and Id1 were independent predictors of lymph node metastasis with adjusted odds ratios for metastasis of 0.02 and 18.77, respectively (Table 2) . To further explore KLF17 and Id1 as biomarkers for identifying lymph node metastasis, we computed the receiver operating curves (ROC) for these two biomarkers independently and in combination (Fig. 5b) . The area under the ROC curve (AUC) for KLF17 and Id1 individually were 0.85 and 0.82, respectively. The AUC increased to 0.95 using the predicted values from the logistic regression model that included both biomarkers. Cut-points were determined for each biomarker based on their ROC curves. Of patients with tumours where KLF17 expression was high and Id1 expression low, the percentage with lymph node metastasis was very low (12.8%; Table 3 ). In contrast, of patients with tumours where there was low KLF17 expression and either high or low Id1 expression, the percentage with lymph node metastasis was very high, ranging from 82.6-100% (Table 3) . Taken together, these analyses indicate that specific combinations of KLF17 and Id1 have high sensitivity or specificity for the detection of patients with or without lymph node metastasis, respectively, and together their expression can distinguish metastatic (lymph node positive) from nonmetastatic (lymph node negative) breast cancer.
DIsCussIoN
We have identified a negative regulator of metastasis using a loss-offunction screen with 168FARN cells. The 168FARN cell line is only defective in the early steps of metastasis such as migration and invasion 23 . Thus, only the metastasis suppressors that inhibit these early steps could be identified and this probably accounts for lack of isolation of other metastasis-suppressing genes in the screen. Screens using other cell lines defective in metastasis steps may identify additional suppressors, as this proof-of-concept screen demonstrates the feasibility of this loss-offunction in vivo selection approach. A saturated or comprehensive screen of metastatic regulators that function at different steps in the metastasis process would require larger numbers of animals.
We have also demonstrated that the loss of KLF17 promotes breast cancer metastasis, at least in part, through the direct regulation of Id1. Other 
METHoDs
Functional screen in an orthotopic animal model and validation of metastasis-suppressing activity. To establish the animal model for the forward genetic screen, 1 × 10 6 168FARN-Luc cells containing a genome-wide mouse RNAi library covering 40,000 genes (System Biosciences) were orthotopically transplanted into the mammary fat pads of 10-week-old BALB/c mice (National Cancer Institute). Five mice were used in the initial screen. Mice bearing luciferase-positive tumours were imaged 7-8 weeks after transplantation with the aid of IVIS 200 Imaging system (Xenogen Corporation). Lung metastasis nodules were isolated and the genomic DNA of lung metastatic cells was purified with the Genomic DNA Purification kit according to manufacturer's instructions (Qiagen). PCRs were performed according to the manufacturer's protocol (SBI). PCR products were cloned with a TA cloning kit (Invitrogen) and sequenced. To validate the hits from the screen, 168FARN-Luc cells were transduced with lentiviruses containing KLF17 shRNA or KLF17 shRNA and KLF17 cDNA, which lacks an shRNA binding site; 1 × 10 6 cells were transplanted into the mammary fat pads of mice and imaged 7-8 weeks later. MCF7 human breast cancer cells (7 × 10 6 cells per mouse) stably expressing KLF17 shRNA were transplanted into the mammary fat pads of female SCID mice (6-8 weeks old). A slow-release pellet of 17β-oestradiol (1.7 mg, 90-day release; Innovative Research of America) was implanted subcutaneously in the dorsal interscapular region before the transplantation of MCF7 cells. Mice bearing luciferase-positive tumours were imaged 6-12 weeks after transplantation with the aid of IVIS 200 Imaging system (Xenogen Corporation).
To analyse the effect of KLF17 overexpression on 4T1 cells, these cells were transduced with a lentivirus containing mouse KLF17 cDNA and transplanted as described above. 168FARN-Luc cells containing non-target shRNA as a control were also transplanted as described above. To determine the number of metastasis nodules on the surface of the lungs, mouse lungs were collected and fixed with Fekete's solution (60% ethanol, 3% formaldehyde and 4% glacial acetic acid) after intratracheal injection of a 15% india ink solution as described previously 54 . The total number of unstained nodules on the lung surface was counted 4-5 weeks after transplantation.
To analyse the effect of Id1 overexpression on 168FARN and MCF7 cells, 168FARN and MCF7 cells were transduced with a lentivirus containing mouse or human Id1 cDNA, respectively, and were transplanted into female Balb/c or SCID mice, respectively, as described above. Mice bearing luciferase-positive tumours were imaged with the aid of IVIS 200 Imaging system (Xenogen Corporation, Hopkinton) as described above.
To study the effect of downregulation of KLF17 expression and Ras in tumour metastasis, NmuMG cells stably expressing a control vector, KLF17 shRNA, oncogenic HRasG12V or co-expressing KLF17 shRNA and HRasG12V were transplanted into SCID mice, as described above. Mice bearing luciferase-positive tumours were imaged with the aid of Xenogen IVIS 200 Imaging system, as described above.
Animal experiment protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the Wistar Institute. Animal procedures were conducted in compliance with the IACUC. Lentiviral shRNA transduction. Cell lines stably expressing KLF17 shRNA, Id1 shRNA or control non-target shRNA were established using a vector-based shRNA technique. All shRNAs were from Sigma. Mouse KLF17 shRNA targets 5´-GCCTGGAAAGTTCTGGAGTTA-3´; human KLF17 shRNA targets 5´-CGACAGTACCTTCTGACGAAAC-3´ and mouse Id1 shRNA targets 5´-CCTACTAGTCACCAGAGACTT-3´. Briefly, lentiviral KLF17 shRNA, Id1 shRNA and control non-target shRNA were from Sigma and lentiviruses were produced by co-transfecting subconfluent human embryonic kidney (HEK) 293T cells with one of the expression plasmids and a packaging plasmid (pMDLg/ pRRE and RSV-Rev) using FuGENE6 as a transfection reagent. Infectious lentiviruses were collected 48 h after transfection, centrifuged to remove cell debris and filtered through 0.45-μm filters (Millipore). 168FARN, MCF7, NMuMG and HMEL cells were transduced with the lentivirus containing KLF17, Id1 or non-target shRNA. The KLF17-or Id1-knockdown efficiency was determined by quantitative real-time PCR. To generate cells stably overexpressing KLF17, Id1 or oncogenic HRasG12V, full-length mouse KLF17 cDNA, Id1 cDNA or oncogenic HRasG12V cDNA was cloned into a lentiviral vector, the lentiviruses were processesed as described above and transduced into cells.
Transwell migration and invasion assay.
In vitro cell migration assays were performed as described previously 55 using Transwell chambers (8-μM pore size; Costar). Cells were allowed to grow to subconfluency (~75-80%) and were serum-starved for 24 h. After detachment with trypsin, cells were washed with PBS, resuspended in serum-free medium and 250 μl of cell suspension (2 × 10 5 cells ml -1 ) was added to the upper chamber. Complete medium was added to the bottom wells of the chamber. The cells that had not migrated were removed from the upper face of the filters using cotton swabs, and the cells that had migrated to the lower face of the filters were fixed with 5% glutaraldehyde solution and stained with 0.5% solution of toluidine blue in 2% sodium carbonate. Images of three random ×10 fields were captured from each membrane and the number of migratory cells was counted. The mean of triplicate assays for each experimental condition was used. Similar inserts coated with Matrigel were used to determine invasive potential in the invasion assay.
Immunoblotting. Standard methods were used for western blotting. Cells were lysed in lysis buffer and total protein contents were determined by the Bradford method. Proteins (30 μg) were separated by SDS-PAGE under reducing conditions and blotted onto a polyvinylidene difluoride membrane (Millipore). Membranes were probed with specific antibodies Blots were washed and probed with respective secondary peroxidase-conjugated antibodies, and the bands visualized by chemoluminescence (Amersham Biosciences). The following antibodies were used: rabbit polyclonal E-cadherin, mouse monoclonal N-cadherin and β catenin (Cell Signaling Technology); rabbit polyclonal ZO-1 (Zymed Laboratories), mouse monoclonal fibronectin and β-actin (Sigma -Aldrich); mouse monoclonal vimentin (Calbiochem); human and mouse KLF17 monoclonal antibodies (generated at the Wistar institute). Primary antibodies were used at a 1:1,000 dilution and secondary antibodies at a 1:5,000 dilution, for immunoblotting.
Immunocytochemistry. Cells were grown on glass coverslips in a six-well plate and washed three times with PBS then fixed in 4% formaldehyde solution and permeabilized with 0.1% Triton X-100 in PBS for 5 min. Cells were blocked with 1% BSA in PBS for 30 min at room temperature. Coverslips were incubated with respective primary antibodies at 1:100 dilutions for 1 h and then washed with PBS and incubated for 1 h with fluorescein-conjugated secondary antibodies at 1:200 dilutions (Molecular Probes). Cells were further washed in PBS and mounted with Vectashield mounting medium containing 4´,6-diamidino-2-phenylindole (DAPI; Vector Laboratories) and analysed using fluorescence microscopy.
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oligonucleotides corresponding to nucleotides to -2134 to -2097 (5´-CCC-CCTT CACCCCACCCCACACCCAATTAGAATAAAC-3´) of the mouse Id-1 promoter with KLF17 consensus binding site or the mutant site 1 (5´-CCCC CTTA-GCTAAGCCCCAAGTACAATTAGAATAAAC-3´) were annealed and end-labelled with [γ-32 P]ATP and T4 polynucleotide kinase (New England Biolabs). Labelled probe (0.3 ng) was incubated with recombinant proteins (100 ng) in a binding buffer containing HEPES (20 mM at pH 7.4), NaCl (50 mM), dithiothreitol (5 mM), EDTA (1 mM), glycerol (5%) and poly (dI:dC; 1 μg) in a total volume of 20 μl, at room temperature for 15 min. In the competition assays, corresponding double-stranded DNA oligonucleotides were end-filled with Klenow using cold dCTP and added to the binding mixture. DNA-protein complexes were resolved on a 6% polyacrylamide gel with 0.5× TBE buffer (25 mM Tris base, 25 mM boric acid and 0.5 mM EDTA) at 150 V for 2 h at room temperature. The gels were dried and the labelled complexes were detected by autoradiography.
Chromatin immunoprecipitation (ChIP) assay. 168FARN cells overexpressing KLF17 were fixed in 1% formaldehyde at 37 °C for 10 min. Cells were washed twice with ice-cold phosphate-buffered saline containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 μg ml -1 aprotinin, and 1 μg ml -1 pepstatin A), scraped, and centrifuged at 4 °C. Cell pellets were resuspended in lysis buffer and sonicated to shear DNA. After sonication, the lysate was centrifuged and the supernatant was diluted 10-fold with ChIP dilution buffer (0.01% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl at pH 8.0, 150 mM NaCl and protease inhibitors). Anti-mouse KLF17, anti-acetyle H3, or normal mouse IgG were added to the supernatant and incubated overnight at 4 °C with rotation. The immunocomplex was precipitated with protein A/G-agarose and washed sequentially with low-salt buffer, high-salt buffer and lithium chloride wash buffer, and eluted with elution buffer (1% SDS, 0.1 M NaHCO 3 and 200 mM NaCl). Reversal of crosslinking was done by heating at 65 °C overnight in the presence of NaCl. DNA was purified using PureLink PCR Purification kit (Invitrogen). The amount of immunoprecipitated DNA was analysed in triplicates using mouse Id1 promoter primer sequence by real-time PCR using an ABI 7500 detection system (Applied Biosystems) with SYBR green PCR kit. Data were analysed using the 2 − Δ Ct method and normalized with input samples as described previously 56 .
RNA isolation, reverse transcription (RT) and real-time PCR analysis. Total RNA was extracted from breast cancer cell lines, frozen primary and metastasis tissues using Trizol total RNA isolation reagent (Invitrogen), according to the manufacturer's instructions and treated with DNase. cDNA was synthesized from total RNA using random hexamers with TaqMan cDNA Reverse Transcription Kit (Applied Biosystems). To determine the levels of KLF17 and Id1 expression, gene primers were designed using Primer Express v3.0 Software and real-time PCR was performed using SYBR Green Jumpstart Taq ReadyMix (Sigma) with Applied Biosystems 7500 Fast Real Time PCR system. The relative amount of expression was calculated from a relative standard curve obtained using log dilutions of cDNA containing the gene of interest. The average of three independent analyses for each gene and sample was calculated and was normalized to the endogenous reference control gene GAPDH.
Microarray Studies. The Illumina MouseWG-6_v2 bead chip was used for the analysis. Total RNA (400 ng) was amplified according to Illumina and aRNA (1.2 µg) hybridized to the arrays. Three biological replicates were analysed for each condition. Data were processed by Bead Studio and the expression levels for signal and control probes were exported. A set of negative control probes was used to calculate the average background level and to determine the signal detection threshold. The probe expression data was normalized using quantile normalization. The data were checked for outliers by calculating an outlier score for each of the samples. First, Spearman correlation coefficients were calculated for every sample pair. Correlation between arrays was >99%.
To reduce the experimental noise, the data were filtered by removing noninformative probes, that is, probes that were not detected in most samples (more than 95%) or probes that did not change at least 1.2-fold between at least two samples. Analysis was carried out using ANOVA and P < 0.05 genes were selected for further analysis.
Clinical specimens. The breast cancer specimens used in this study were collected at the time of surgery from previously untreated patients. Samples were snapfrozen immediately and stored at -80 o C. Total RNA was isolated from frozen tissue with Trizol reagent (Invitrogen). Specimens were collected under the approval of the local Institutional review board and processed using procedures approved by the HIPAA (Health Insurance Portability and Accountability) act. The clinical outcome was the presence of lymph node metastases at the time of diagnosis.
Microarray data accession number. The complete microarray data are available in the Gene Expression Omnibus (GEO; accession number, GSE17081). 
